

CKD-ADC, A Novel Antibody-Drug Conjugate Targeting cMET in Solid Tumors

Chong Kun Dang



ONCOLOGY	Preclinical
Product Type	Antibody-Drug Conjugate
Indication	Solid cancer, Non-small cell lung cancer
Target	cMET
MoA(Mechanism of Action)	Delivering cytotoxic drugs (MTs inh.) specifically to cancer cells cMET signaling inhibition
Competitiveness	Next-generation ADC technology: Site-specific conjugation for precise and uniform DAR control, leading to superior blood stability. Antibody engineering: Enhanced target signaling inhibition through advanced antibody modifications.
Development Stage	Preclinical
Route of Administration	Intravenous